A pilot study in the efficacy and safety of gemfibrozil in a pediatric population

Journal of Clinical Lipidology

Volumn 2, Issue 2, 2008, Pages 106-111

  Smalley, Courtney M ^a   Goldberg, Stanley J ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Children; Cholesterol lowering drugs; Gemfibrozil; Lipoproteins; Metabolic syndrome; Prevention

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BACKACHE; BLOOD PRESSURE; BODY COMPOSITION; BODY FAT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MORNING DOSAGE; MYALGIA; PILOT STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; WAIST CIRCUMFERENCE;

EID: 40649129013     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2008.02.003     Document Type: Article

References (29)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 9326 (2002) 7-22
2. Scandinavian Simvastatin Survival Study Writing Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
3. 4S Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93 (2004) 136-141
4. LaRosa J.C., He J., and Vuppurturi S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282 (1999) 2340-2346
5. Morgan J.M., Capuzzi D.M., and Guyton J.R. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 82 12A (1998) 29U-34U
6. Guyton J.R., Blazing M.A., Hagar J., et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 160 (2000) 1177-1184
7. Matthan N.R., Giovanni A., Schaefer E.J., Brown B.G., and Lichtenstein A.H. Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. J Lipid Res 44 (2003) 800-806
8. Frick M.H. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
9. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA 248 (1982) 1465-1477
10. Rubins H.B. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
11. Frick M.H. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 96 (1997) 2137-2143
12. Rossner S., and Oro L. Fenofibrate therapy of hyperlipoproteinaemia: a dose-response study and a comparison with clofibrate. Atherosclerosis 38 (1981) 273-282
13. Bhatnagar D. Lipid-lowering drugs in the management of hyperlipidaemia. Pharmacol Ther 79 (1998) 205-230
14. Sudhop T., Lütjohann D., Kodal A., et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106 (2002) 1943-1948
15. Dujovne C.A., Ettinger M.P., et al., Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, in ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 90 (2002) 1092-1097
16. Knopp R.H., Gitter H., et al., Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 24 (2003) 729-741
17. McMahan C.A., McGill H.C., Gidding S.S., et al. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) research group. PDAY risk score predicts advanced coronary artery atherosclerosis in middle-aged persons as well as youth. Atherosclerosis 190 (2007) 370-377
18. de Jongh S., Lilien M.R., op't Roodt J., Stroes E.S., Bakker H.D., and Kastelein J.J. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 40 (2002) 2117-2121
19. Wiegman A., Hutten B.A., de Groot E., et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 292 (2004) 331-337
20. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., and Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
21. de Ferranti S.D., Gauvreau K., Ludwig D.S., Neufeld E.J., Newburger J.W., and Rifai N. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation 110 (2004) 2494-2497
22. Moreno L.A., Pineda I., Rodriguez G., Fleta J., Sarría A., and Bueno M. Waist circumference for the screening of the metabolic syndrome in children. Acta Paediatr 91 (2002) 1307-1312
23. Stampfer M.J., Krauss R.M., Ma J., Blanche P.J., Holl L.G., and Hennekens C.H. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276 (1996) 882-888
24. McNamara J.R., Jenner J.L., Li Z., Wilson P.W., and Schaefer E.J. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb 12 (1992) 1284-1290
25. Tai E.S., Collins D., Robins S.J., et al. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis 187 (2006) 153-160
26. Buyukcelik M., Anarat A., Bayazit A.K., et al. The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome. Turk J Pediatr 44 (2002) 40-44
27. Wheeler K.A., West R.J., Lloyd J.K., and Barley J. Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child 60 (1985) 34-37
28. Durnin J.V.G.A., and Wormersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged 16 to 72 years. Br J Nutr 32 (1974) 77-97
29. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502